TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15744240

Group type: EXPERIMENTAL
Intervention: PCV7 vaccine before stem cell collection
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PCV7 vaccine after autoHCT
Number of subjects: 61

Group type: COMPARATOR
Intervention: No vaccine before stem cell collection
Number of subjects: 61
Study: 11929445

Group type: EXPERIMENTAL
Intervention: Educational intervention about tardive dyskinesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 56
Study: 9484992

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: -455AA genotype
Number of subjects: 0
Study: 7709282

Group type: EXPERIMENTAL
Intervention: Lumbar belt
Number of subjects: 22

Group type: COMPARATOR
Intervention: No lumbar belt
Number of subjects: 22
Study: 2663735

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg twice daily (plus placebo once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 500 mg/125 mg thrice daily
Number of subjects: 60
Study: 1106196

Group type: EXPERIMENTAL
Intervention: Prophylactic cephalosporins
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31615279

Group type: EXPERIMENTAL
Intervention: Preserved brimonidine 0.15%
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Preservative-free brimonidine 0.15%
Number of subjects: 21
Study: 31546833

Group type: EXPERIMENTAL
Intervention: Scabies group (6628 patients)
Number of subjects: 33537

Group type: COMPARATOR
Intervention: Control group (26,509 patients)
Number of subjects: 33537
Study: 28590452

Group type: EXPERIMENTAL
Intervention: Genistein 54 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26052790

Group type: EXPERIMENTAL
Intervention: Daily sensorimotor enrichment administered by parents along with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subset of sensory stimuli
Number of subjects: 0
Study: 23487599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: 1000 U/d cholecalciferol
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: 2000 U/d cholecalciferol
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: 4000 U/d cholecalciferol
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (each additional 1000 U/d)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D increase (1-ng/mL)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 283
Study: 22039430

Group type: EXPERIMENTAL
Intervention: Single-dose (4 mL 1% TFV gel)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multiple-dose (QD or BID for 2 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Single-dose (SD)
Number of subjects: 49
Study: 19451442

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Sorafenib (after censoring placebo patients who crossed over)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo (after censoring patients who crossed over)
Number of subjects: 903
Study: 16387891

Group type: EXPERIMENTAL
Intervention: Semi-elemental formula (Peptamen, 35 kcal/kg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polymeric formula (Sondalis-Iso, 35 kcal/kg/d)
Number of subjects: 30
Study: 12816740

Group type: EXPERIMENTAL
Intervention: cilomilast, 15 mg two times a day
Number of subjects: 59

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study: 10370734

Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary artery bypass
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saphenous vein grafts only
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of uni- or bilateral internal mammary artery(ies) with saphenous vein grafts
Number of subjects: 73
Study: 8677206

Group type: COMPARATOR
Intervention: IDDM without diabetic nephropathy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IDDM with diabetic nephropathy (conservatively treated)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IDDM with end stage renal failure (haemodialysis)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic renal failure of non-diabetic origin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: End stage renal failure of non-diabetic origin (haemodialysis)
Number of subjects: 12
Study: 1882375

Group type: EXPERIMENTAL
Intervention: Amrinone (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amrinone (first bolus)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amrinone (second bolus)
Number of subjects: 20
Study: 6135440

Group type: EXPERIMENTAL
Intervention: Ranitidine (24 h therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 0
Study: 28183399

Group type: EXPERIMENTAL
Intervention: 4‐STEPS program (Motivational Interviewing and SR-skills training)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 91
Study: 26799522

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL/MPS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tacrolimus (TAC/MPS)
Number of subjects: 119
Study: 24132979

Group type: EXPERIMENTAL
Intervention: Prenatal high protein and energy supplementation
Number of subjects: 1459

Group type: COMPARATOR
Intervention: Maternal supplementation during lactation
Number of subjects: 1459
Study: 22285180

Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 19639458

Group type: EXPERIMENTAL
Intervention: Tenaculum application to the cervix during IUI (Group 2, n=232)
Number of subjects: 468

Group type: COMPARATOR
Intervention: No tenaculum application to the cervix during IUI (Group 1, n=236)
Number of subjects: 468
Study: 17199725

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 70/30)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 16291982

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg
Number of subjects: 1036
Study: 12200523

Group type: EXPERIMENTAL
Intervention: Anti-allergic mattress covers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9761503

Group type: EXPERIMENTAL
Intervention: Oxalate-rich diet (1211 mg calcium/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Calcium and oxalate-rich diet (3858 mg calcium/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Free-choice diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxalate-rich diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Calcium and oxalate-rich diet
Number of subjects: 14
Study: 7835212

Group type: COMPARATOR
Intervention: HLA‐A, ‐B, ‐C, ‐DR, and ‐DQ typing
Number of subjects: 50

Group type: COMPARATOR
Intervention: HLA‐DR2, ‐DR5 and ‐DQ1
Number of subjects: 50

Group type: COMPARATOR
Intervention: HLA haplotype analysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: HLA haplotypes A1,B17 and DR2,DQ1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GLOI phenotype GLOI 2‐1
Number of subjects: 50
Study: 2970855

Group type: EXPERIMENTAL
Intervention: Fosenopril
Number of subjects: 11
Study: 31856981

Group type: EXPERIMENTAL
Intervention: 4°C hypothermic perfusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: 24°C control
Number of subjects: 80
Study: 28476288

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily (blinded phase)
Number of subjects: 10180

Group type: EXPERIMENTAL
Intervention: Atorvastatin (non-blinded phase)
Number of subjects: 10180
Study: 25720930

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Surgical ligation with attempted stripping/excision
Number of subjects: 106
Study: 23353641

Group type: EXPERIMENTAL
Intervention: UDCA (17‐23 mg/kg/day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Overall (both UDCA and placebo)
Number of subjects: 198
Study: 20219315

Group type: EXPERIMENTAL
Intervention: Training focused on patient-centered communication about behavioral risk factors
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 28
Study: 19081408

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg
Number of subjects: 659

Group type: COMPARATOR
Intervention: UFH (activated clotting time‐adjusted)
Number of subjects: 659
Study: 17494925

Group type: EXPERIMENTAL
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 10565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10565

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 10565
Study: 15508985

Group type: EXPERIMENTAL
Intervention: Splinted implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unsplinted implants
Number of subjects: 36
Study: 11677200

Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept 25 mg twice weekly
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9155608

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 7957014

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 691
Study: 3116695

Group type: EXPERIMENTAL
Intervention: Modified TPN (15% dextrose, fat, and 5% amino acids)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional TPN (25% dextrose and 4.25% amino acids)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both TPN regimens
Number of subjects: 88
Study: 2694612

Group type: EXPERIMENTAL
Intervention: Mildronate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31879945

Group type: EXPERIMENTAL
Intervention: Pixantrone + rituximab (PIX + R)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Gemcitabine + rituximab (GEM + R)
Number of subjects: 312
Study: 30904703

Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Alchemilla vulgaris
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel with propyleneglycolic extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogels with A. vulgaris extracts
Number of subjects: 0
Study: 28767558

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 66
Study: 25821958

Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunting
Number of subjects: 32
Study: 23765713

Group type: EXPERIMENTAL
Intervention: Primary plus prophylactic upper neck irradiation (UNI)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Primary plus whole-neck irradiation (WNI)
Number of subjects: 301
Study: 21106207

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Non-adherent patients
Number of subjects: 174
Study: 19961001

Group type: EXPERIMENTAL
Intervention: Meteospazmil
Number of subjects: 0
Study: 17405171

Group type: EXPERIMENTAL
Intervention: 23G needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: 21G needle
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 100
Study: 15304381

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 422

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 422
Study: 11331640

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg/month for 6 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA; 30 mg/day for 6 months)
Number of subjects: 47
Study: 9013162

Group type: EXPERIMENTAL
Intervention: Low-dose midazolam (35 micrograms/kg) and pethidine (700 micrograms/kg in 48 patients, 500 micrograms/kg in 102 patients)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam and placebo pethidine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pethidine and placebo midazolam
Number of subjects: 150
Study: 7700028

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 2975995

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 15 pmol kg‐1 min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 0.003 pmol kg‐1 min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AVP + ANF
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9

Group type: COMPARATOR
Intervention: P + P
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AVP + P
Number of subjects: 9
Study: 30106888

Group type: EXPERIMENTAL
Intervention: Phase-randomized weak coherent states with different mean photon numbers
Number of subjects: 0
Study: 26785249

Group type: EXPERIMENTAL
Intervention: Behavioral intervention delivered over 20 weeks
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 325
Study: 23340794

Group type: EXPERIMENTAL
Intervention: 2 g of sodium restriction on habitual diet (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 39
Study: 22438530

Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (clopidogrel + aspirin)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (clopidogrel + aspirin)
Number of subjects: 2013
Study: 20536600

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 880

Group type: COMPARATOR
Intervention: Diclofenac 50 mg twice daily
Number of subjects: 880
Study: 17087998

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study: 15502893

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment of chronic tinnitus
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Self-rating instrument for SoC
Number of subjects: 125
Study: 14736356

Group type: EXPERIMENTAL
Intervention: Single-needle acupuncture at Chengjiang (midline between lower lip and chin)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham acupuncture at a superficial point (tip of the chin)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 41
Study: 10618937

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tramadol 50 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tramadol 75 mg
Number of subjects: 75
Study: 8951985

Group type: COMPARATOR
Intervention: Nicotine patch (0 mg) during abstinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine patches (10 mg, 20 mg, 30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine abstinence (0 mg patch)
Number of subjects: 0
Study: 1673577

Group type: EXPERIMENTAL
Intervention: Bopindolol (a beta-blocker with a slightly expressed ISA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Metoprolol (cardioselective beta-blocker)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 7074402

Group type: EXPERIMENTAL
Intervention: Midazolam (0.30 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiopentone (3.99 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thiopentone with diazepam premedication
Number of subjects: 48

Group type: COMPARATOR
Intervention: Midazolam with diazepam premedication
Number of subjects: 48
Study: 29514030

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 27076599

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous alteplase administration (drip and ship)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presentation during work hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drip-ship transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloon guide catheter use
Number of subjects: 0
Study: 24577626

Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg once weekly and PLD 40 mg/m(2) once every 4 weeks
Number of subjects: 19
Study: 22720738

Group type: EXPERIMENTAL
Intervention: Individualised cooled dialysate (set at 0.5°C less than the patient's own temperature, up to a maximum of 36°C)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional dialysate temperature of 37°C
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Individualised cooled dialysate
Number of subjects: 73
Study: 21058483

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 63

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 63
Study: 17937357

Group type: EXPERIMENTAL
Intervention: BOOT Camp Survival Training for Navy Recruits‐A Prescription (BOOT STRAP)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 1199
Study: 15809829

Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 12
Study: 12465157

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 9468424

Group type: EXPERIMENTAL
Intervention: Midazolam (5.3±1.1 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam (11.2±2.3 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 200
Study: 8540665

Group type: EXPERIMENTAL
Intervention: Silicone catheter (23G, 15 cm long)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Teflon cannula (18G, 4.4 cm long)
Number of subjects: 79
Study: 2092025

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cimetidine (smokers)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (smokers)
Number of subjects: 76
Study: 733569

Group type: EXPERIMENTAL
Intervention: VM 26 (podophyllin derivative) administered alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no VM 26)
Number of subjects: 21
Study: 31116908

Group type: EXPERIMENTAL
Intervention: ProGlide (PG)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Prostar XL (PS)
Number of subjects: 746
Study: 28704534

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including dietary intervention with hypocaloric diet and assisted personalized physical aerobic and anaerobic activities for 3 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 14
Study: 26202594

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus placebo plus weekly paclitaxel (OP)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus bevacizumab plus paclitaxel (OBP)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab plus paclitaxel (BP)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Onartuzumab arms (OBP, OP)
Number of subjects: 185
Study: 23643176

Group type: EXPERIMENTAL
Intervention: Uracil/tegafur (UFT) and cisplatin (400 mg/m² UFT on days 1-14 and 29-42, 80 mg/m² cisplatin on days 8 and 36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vinorelbine and cisplatin (20 mg/m² vinorelbine on days 1, 8, 29, and 36, 80 mg/m² cisplatin on days 1 and 29)
Number of subjects: 70
Study: 21320300

Group type: EXPERIMENTAL
Intervention: Multifactor intervention including motivational aspects related to adherence (beliefs and behaviour), cognitive aspects (information about illness), skills (inhaled technique training), and reinforcement of cognitive-emotional aspects during four visits over one year.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 140
Study: 19377380

Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with low-systemic heparin (125 IU/kg, ACT >250 s)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with full dose heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Uncoated controls (Vision HFO, Gish, USA)
Number of subjects: 100
Study: 17297382

Group type: EXPERIMENTAL
Intervention: Cellulose sulfate (CS) gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: KY Jelly
Number of subjects: 36
Study: 15567011

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) + sulfadoxine‐pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg over 3 days) + sulfadoxine‐pyrimethamine
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Amodiaquine + artesunate (4 mg/kg daily for 3 days)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Amodiaquine+sulfadoxine‐pyrimethamine
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 418